GLP-1 Drugs Shrink Fat but Also Muscle — New Strategies to Protect Lean Mass

A revolution in obesity pharmacotherapy arrived with the FDA approval of semaglutide (2021) and tirzepatide (2023), delivering mean weight losses of 14.9% and 20.9% respectively — far exceeding any prior medication. Tirzepatide's dual GLP-1/GIP receptor agonism allows a higher proportion of patients to hit 20% weight loss benchmarks (57% vs. 32% for semaglutide). These drugs also carry powerful disease-modifying effects: cardiovascular risk reduction, improvements in heart failure with preserved ejection fraction, chronic kidney disease progression slowing, and obstructive sleep apnea relief.

Because obesity is chronic, these medications must be taken indefinitely. Withdrawal studies (STEP 1 Extension, STEP 4, SURMOUNT 4) confirm that stopping the drug leads to substantial weight regain and loss of cardiometabolic benefits. This necessity for lifelong use means the drugs will increasingly be prescribed to adults over 60 — a population already experiencing progressive muscle and bone loss even at stable weight.

The body composition data are concerning. DEXA substudies from STEP 1 and SURMOUNT 1 show that approximately 45% of weight lost on semaglutide is lean mass, compared to ~26% for tirzepatide. The "Quarter FFM Rule" benchmark suggests no more than 25% of lost weight should be fat-free mass, meaning semaglutide clearly exceeds this threshold. Evidence from the Look AHEAD study — which followed over 5,000 adults with type 2 diabetes (mean baseline age 59) for a decade — illustrates the downstream risk: the intensive lifestyle intervention group showed a statistically significant 39% increased risk of frailty fractures (HR=1.39, 95% CI 1.02–1.89) compared to controls, despite modest overall weight differences. Crucially, weight regain in that group restored fat but not lean mass.

Several strategies are under investigation to mitigate lean mass loss. Next-generation NuSH-based molecules that incorporate glucagon receptor agonism (survodutide, retatrutide) or amylin receptor activity may alter body composition favorably, as glucagon promotes lipolysis and amylin has been associated with better lean preservation. Early data suggest these combinations could shift the fat-to-lean loss ratio. More targeted is the emerging class of myostatin-activin pathway inhibitors (MAPi). Bimagrumab, an anti-ActRII antibody, has shown striking results in small trials: in one study of adults with type 2 diabetes and obesity, bimagrumab reduced fat mass by ~20% while increasing lean mass by ~3.6% over 48 weeks. A combination study pairing bimagrumab with semaglutide is underway and represents the most direct approach to simultaneously maximizing fat loss while protecting muscle.

Selective androgen receptor modulators (SARMs) are also mentioned as a theoretical tool but evidence in this context remains sparse and regulatory hurdles significant. The review concludes that for the full disease-modifying potential of these drugs to be realized — especially in older patients — demonstrating safe long-term body composition outcomes is essential, and lean mass preservation strategies must be co-developed alongside weight loss pharmacotherapy.